180 Life Sciences Corp
For the period ended Dec 31, 2023. Filed Mar 25, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 25, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10–K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| 180 LIFE SCIENCES CORP. | ||
| Date: March 22, 2024 | /s/ James N. Woody | |
|---|---|---|
| By: | James N. Woody, Chief Executive Officer (Principal Executive Officer) |
| Date: March 22, 2024 | /s/ Ozan Pamir | |
|---|---|---|
| By: | Ozan Pamir, Chief Financial Officer (Principal Financial and Accounting Officer) |
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ James N. Woody | Chief Executive Officer and Director | March 22, 2024 |
| James N. Woody | (Principal Executive Officer) | |
| /s/ Ozan Pamir | Chief Financial Officer | March 22, 2024 |
| Ozan Pamir | (Principal Financial and Accounting Officer) | |
| /s/ Lawrence Steinman | Executive Chairman and Director | March 22, 2024 |
| Lawrence Steinman | ||
| /s/ Blair Jordan | Lead Director | March 22, 2024 |
| Blair Jordan | ||
| /s/ Omar Jimenez | Director | March 22, 2024 |
| Omar Jimenez | ||
| /s/ Ryan L. Smith | Director | March 22, 2024 |
| Ryan L. Smith | ||
TABLE OF CONTENTS
| Page | |
| REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM (PCAOB ID 688) | F-2 |
|---|---|
| CONSOLIDATED FINANCIAL STATEMENTS: | |
| Consolidated Balance Sheets as of December 31, 2023 and 2022 | F-3 |
| Consolidated Statements of Operations and Comprehensive Loss For the Years Ended December 31, 2023 and 2022 | F-4 |
| Consolidated Statements of Changes in Stockholders’ (Deficit) Equity For the Years Ended December 31, 2023 and 2022 | F-5 |
| Consolidated Statements of Cash Flows For the Years Ended December 31, 2023 and 2022 | F-7 |
| Notes to Consolidated Financial Statements | F-9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.